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S
ystemic sclerosis (SSc; also 
referred to as “scleroderma”) is a 
rare but debilitating autoimmune 
disease clinically characterized by skin 
thickening and signs and symptoms 
of vasculopathy, which can involve 
the heart, lungs, kidneys, and gut. 
The disease spectrum can range from 
limited to diffuse disease, depending 
on the distribution of skin involvement, 
speciﬁ  city of autoantibodies, and type 
of organ involvement. Patients with 
extensive skin thickening and organ 
dysfunction in particular are at risk of 
premature mortality [1]. 
The disease poses a challenge for 
the treating clinician, as no proven 
therapy exists that improves outcome, 
although recent data indicate that 
cyclophosphamide-based regimens may 
be effective in a subset of patients with 
early disease [2]. The etiology of SSc 
remains enigmatic, and few genetic and 
environmental predisposing factors 
have been identiﬁ  ed. 
Pathogenesis of SSc
Nevertheless, important aspects 
of its pathogenesis have been 
elucidated, particularly those related 
to progressive ﬁ  brosis, which is one 
of the hallmarks of the disease. 
Transforming growth factor β (TGFβ) 
is a pivotal cytokine in this process; it 
is a pleiotropic cytokine that induces 
matrix accumulation, regulates 
lymphocyte function and promotes 
endothelial cell apoptosis. Binding 
of TGFβ to the type II TGFβ receptor 
triggers its heterodimerization 
with, and activation of, type I TGFβ 
receptor. This activation results in a 
downstream signaling cascade with 
phosphorylation of speciﬁ  c receptor-
regulated Smad (R-Smad) proteins 
(Smad2/3), which partner with Smad4 
after dissociation from the TGFβ 
receptor (Figure 1). Smad2/3–Smad4 
oligomers migrate to the nucleus, 
recruit other gene regulatory proteins, 
and activate transcription of speciﬁ  c 
target genes. In the absence of 
ligand stimulation, Smads reside 
predominantly in the cytoplasm; 
translocation of the activated R-Smad–
Smad4 complex into the nucleus is a 
key step in signal transduction. 
Skin ﬁ  broblasts from patients 
with SSc express relatively high levels 
of TGFβ receptor, and contain high 
concentrations of R-Smad3 in the 
nucleus, while inhibitory Smad7 is 
functionally defective [3–5]. These 
and other data suggest that TGFβ 
signaling is constitutively activated 
in SSc ﬁ  broblasts, thus contributing 
to aberrant extracellular matrix 
synthesis. The important role of 
Smads in ﬁ  brosis is illustrated by 
the ﬁ  nding that Smad3-deﬁ  cient 
mice are resistant to different forms 
of ﬁ  brosis. Not surprisingly, the 
TGFβ/Smad axis has been identiﬁ  ed 
as a therapeutic target in ﬁ  brotic 
conditions such as SSc. 
A New Study in a Mouse Model 
of SSc
A study published in this issue of PLoS 
Medicine by Liu et al. [6] shows that, 
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Figure 1. Simpliﬁ  ed Model for Smad-Dependent Signaling Pathway Activated by TGFβ
Showing the Consecutive Steps following TGFβ Binding to the Type II TGFβ receptor 
Step 1: TGFβ binding to a type II receptor causes the receptor to recruit and phosphorylate a type 
I receptor. Step 2: phosphorylated type I receptor recruits and phosphorylates Smad2 or Smad3, 
upon which the Smads open up and expose a dimerization surface. Step 3: phosphorylated Smad2 
or Smad3 dissociates from the receptor and oligomerizes with inhibitory Smad4. Step 4: the 
Smad2/3–Smad4 complex migrates to the nucleus, recruits other gene regulatory proteins (blue), 
and activates transcription of speciﬁ  c target genes. PLoS Medicine  |  www.plosmedicine.org 1231
in a hybrid human SSc skin–severe 
combined immunodeﬁ  cient mouse 
xenotransplant model, stabilizing 
microtubules using paclitaxel (Taxol; 
a powerful anticancer agent and 
angiogenic inhibitor isolated from 
the bark of the Paciﬁ  c yew tree) 
reduces production of phosphorylated 
Smad2/3 and expression of 
COL1A2 (one of the genes involved 
in production of collagen, whose 
promoter contains multiple Smad-
binding elements). The end result is 
to lessen ﬁ  brosis histologically. The 
study takes advantage of an important 
animal model for scleroderma, the 
engraftment of SSc skin samples in 
immunodeﬁ  cient mice. These samples 
have previously been shown to retain 
their phenotype and abnormal Smad 
expression [7]. The study also builds 
on previous work that has shown 
that microtubules provide a negative 
feedback loop in TGFβ signaling in 
cell lines by forming a complex with 
endogenous Smad2, Smad3, and 
Smad4, sequestering R-Smads away 
from the TGFβ receptor [8]. Taken 
together, these studies suggest that 
modulating TGFβ/Smad signaling with 
paclitaxel may be an effective means to 
treat skin ﬁ  brosis. 
The Role of Other Signaling 
Cascades
However, recent data indicate that 
other signaling cascades are also 
perturbed [9], and it is, therefore, 
conceivable that the beneﬁ  cial effects 
of paclitaxel on scleroderma skin 
thickening are not solely due to 
changes in TGFβ/Smad signaling. One 
of the read-outs of ﬁ  brogenesis in the 
study of Liu et al. is reduced expression 
of COL1A2, an essential gene involved 
in the biosynthesis of collagen. 
However, this process is complex: 
extensive posttranslational modiﬁ  cation 
of the COL1A2 gene product occurs 
during the ﬁ  brotic process in which 
many key enzymes such as telopeptide 
lysyl hydroxylase are involved [10]. 
Future studies should address the 
effect of paclitaxel on the expression 
of the wide array of enzymes involved 
in ﬁ  brosis by genome-wide expression 
studies in patients treated with 
paclitaxel or ex vivo on scleroderma 
skin samples.
Next Steps
By contrast, scleroderma-like changes 
in patients with cancer have been 
ascribed to the use of taxanes, 
including paclitaxel [11]. Whether, as 
suggested by Liu et al., this paradoxical 
effect on skin relates to the use of low 
doses in the mouse model described 
by them rather than the high doses 
used in patients with cancer remains 
to be determined, but the point 
underscores the need for further 
studies. Further work is also needed on 
the in vivo effects of paclitaxel on the 
vasculature and immune abnormalities 
in SSc patients, which are difﬁ  cult to 
evaluate using scleroderma skin grafts 
in immunodeﬁ  cient mice. At the low 
doses used in the studies by Liu et al. 
no antiangiogenic effect was found. 
Clearly, there is a delicate balance 
between microtubule stabilizing and 
destabilizing forces in scleroderma, 
which paclitaxel may alter. These 
ﬁ  ndings suggest, however, that a small 
pilot study of such therapy in selected 
patients with diffuse SSc, though a 
daring endeavor, may be worth the 
risk.  
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